Table 2.
In vitro antimicrobial susceptibility testing of common pathogens from full-term neonatal cases with proven meningitis.
| Organism | PEN | AMP | GEN | CLI | VAN | LNZ | CTX | CRO | FEP | MEM | ESBL (+) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GBS | 42/43 (97.7) | 25/25 (100.0) | – | 6/37 (16.2) | 43/43 (100.0) | 40/40 (100.0) | 11/11 (100.0) | 41/43 (95.3) | – | 10/10 (100.0) | – |
| E. coli | – | 10/35 (28.6) | 24/38 (63.2) | – | – | – | 19/38 (50.0) | 17/30 (56.7) | 31/35 (88.6) | 25/25 (100.0) | 7/17 (41.2) |
| CoNS | 3/32 (9.4) | – | 19/30 (63.3) | 18/32 (56.3) | 32/32 (100.0) | 31/31 (100.0) | – | – | – | – | – |
| Enterobacteriaceae (except E. coli) | – | 0/8 (0.0) | 6/8 (75.0) | – | – | – | 3/8 (37.5) | 2/2 (100.0) | 4/7 (57.1) | 6/6 (100.0) | – |
| Enterococcus | 2/4 (50.0) | 4/6 (66.7) | 5/6 (83.3) | – | 7/7 (100.0) | 6/6 (100.0) | – | – | – | – | – |
Numbers represent susceptible pathogens/pathogens tested (% susceptible). PEN, penicillin; AMP, ampicillin; GEN, gentamicin; CLI, clindamycin; VAN, vancomycin; LNZ, linezolid; CTX: cefotaxime; CRO, ceftriaxone; FEP, cefepime; MEM, meropenem; ESBL (+), extended spectrum beta-lactamase (+).